



Hessisches Sozialministerium · Postfach 31 40 · D-65021 Wiesbaden

Geschäftszeichen (im Antwortschreiben bitte angeben)
VIII 7A 181 6420

Per Telefax

Bearbeiter/in: Herr Dr. Michael Binger

Bundesinstitut für Arzneimittel und Medizinprodukte

Direkte Kommunikation (Durchwahl):

Oberste Landesgesundheitsbehörden

Telefon: (0611) 8 17 - 3851

Arzneimittelkommissionen der Apotheker und Ärzte

Telefax: (0611) 8 17 - 3850

E-Mail: michael.binger@hsm.hessen.de

nachrichtlich:

Wiesbaden, April 2008

Landesärztekammer Hessen

Landesapothekerkammer Hessen

Zentralstelle der Länder für Gesundheitsschutz bei
Arzneimitteln und Medizinprodukten

Abwehr von Arzneimittelrisiken

Rückruf mehrerer Chargen der Fertigarzneimittel Heparin Natrium Braun „Multi“ 10 000 I.E./ml und Heparin Sodium 25 000 I.U./5ml, der Firma B. Braun Melsungen AG, Carl-Braun-Str. 1, 34212 Melsungen

Anlage

RAS-Formular des Regierungspräsidiums Darmstadt mit Anhang

Die Fa. B. Braun Melsungen AG ruft eigenverantwortlich mehrere Chargen der o.g. Fertigarzneimittel zurück.

Die Überprüfung von bereits ausgelieferten Chargen von unfraktioniertem Heparin zur parenteralen Anwendung unter Verwendung der im Stufenplanbescheid vom BfArM vom 11. März 2008 ab dem 1. April 2008 verbindlichen Analysenmethoden auf Verunreinigungen hat in den als Anlage dem RAS-Formular beigefügten, dort aufgeführten Chargen analytische Auffälligkeiten ergeben.

Schwerwiegende, unerwünschte Arzneimittelwirkungen wurden dem pharmazeutischen Unternehmer bis dato nicht bekannt. Der Produktrückruf erfolgt insoweit vorsorglich.

Details zur Distribution bitte ich dem Annex der Anlage zu entnehmen.

Nach Auskunft der B. Braun Melsungen AG sind die Zulassungsinhaber in Belgien (B. Braun Medical N.V., Woluwelaan 140b, 1813 Diegem) und Portugal (B. Braun Medical Lda., Queluz Park, Est. Consiglieri Pedroso, 80, Queluz de Baixo, 2730-053 Barcarena) informiert und rufen die betroffenen Produkte in eigener Zuständigkeit zurück.

Nach Information der Firma wurden zudem die Kunden über den Rückruf informiert. Die Veröffentlichung in der pharmazeutischen Fachpresse erfolgt in der nächsten Ausgabe.

Das Regierungspräsidium Darmstadt überwacht den Rückruf.

Im Auftrag

Dr. Michael Binger

Annex to section 4: Product

Heparin Sodium 25 000 I.U./5 ml

in Germany, Australia, Azerbaijan, Bulgaria, Columbia, Georgia, Kazachstan, Luxembourg, Russia, El Salvador, Angola, Bahrain, Barbados, Palestine, Ivory Coast, Fiji, Indonesien, Qatar, Lebanon, Libyen, Malawi, Namibia, Congo, Slovenia, Suriname, United Arabic Emirates

Heparin Natrium Braun „Multi“10 000 I.E. /ml

in Germany

Annex to section 5: Marketing Authorisation Number

for Heparin Sodium 25 000 I.U./5 ml

DE: 1708.00.00

AZ: SN-026 00035

BG: 20000368

CO: M-004859

GE: 2741

KZ: PT-5-LS-№008883

LU: 667/83/06/0203

RU: 012984/01

SV: 22.490

For Heparin Natrium Braun „Multi“10 000 I.E. /ml

DE: 1708.03.00

Annex to section 6: Brand/Trade Name

for Heparin Sodium 25 000 I.U./5 ml

DE: Heparin Natrium Braun 25000 I.E./5 ml

AZ: Heparin Sodium Braun 25 000 I.U./5ml

BG: Heparin Natrium 25 0000 I.U. / 5 ml

CO: Heparina Sodica Iny. 5000 U.I./ml

GE: Heparin Sodium Braun 25 000 I.U./5ml

KZ: Heparin Sodium Braun 25 000 I.U./5ml

LU: Heparin Natrium Braun 25000 I.E./5 ml

RU: Heparin Sodium Braun

SV: Heparina Sodica Iny. 5000 U.I./ml

For Heparin Natrium Braun „Multi“10 000 I.E. /ml

DE: Heparin Natrium Braun „Multi“10 000 I.E. /ml

Annex to section 9: Strength

for Heparin Sodium 25 000 I.U./5 ml

all concerned countries

25000 I.U./5 ml

For Heparin Natrium Braun „Multi“10 000 I.E. /ml

Germany

10000 I.U./ ml

Annex to section 12: Pack size and presentation

for Heparin Sodium 25 000 I.U./5 ml

all concerned countries

10 x 5 ml glass vials

For Heparin Natrium Braun „Multi“10 000 I.E. /ml

Germany

glass vials in packs of 1x 10 ml, 5 x 10 ml, 1x 20 ml, 2x 20 ml

Annex to section 14: Marketing Authorisation Holder

Germany (for both products), **Australia, Azerbaijan, Bulgaria, Columbia, Georgia, Kazachstan, Luxembourg, Russia, El Salvador, Angola, Bahrain, Barbados, Palestine, Ivory Coast, Fiji, Indonesien, Qatar, Lebanon, Libyen, Malawi, Namibia, Congo, Slovenia, Suriname, United Arabic Emirates**

B. Braun Melsungen AG

Carl-Braun-Str. 1

34212 Melsungen, Germany

Annex to section 19: Information on distribution

Germany, Australia, Azerbaijan, Bulgaria, Columbia, Georgia, Kazachstan, Luxembourg, Russia, El Salvador, Angola, Bahrain, Barbados, Palestine, Ivory Coast, Fiji, Indonesien, Qatar, Lebanon, Libyen, Malawi, Namibia, Congo, Slovenia, Suriname, United Arabic Emirates

Annex to section 10: batches

Artikelnr.	Bezeichnung	Land	Charge
2042045	HEPARIN NATR."MULTI"100.000 V 10ML DE	DE	6132N01
2042045	HEPARIN NATR."MULTI"100.000 V 10ML DE	DE	6252N01
2042045	HEPARIN NATR."MULTI"100.000 V 10ML DE	DE	7421N01
2042053	HEPARIN NATRIUM "MULTI" SET 2X200000 IE	DE	6133N01
2042053	HEPARIN NATRIUM "MULTI" SET 2X200000 IE	DE	6215N01
2042053	HEPARIN NATRIUM "MULTI" SET 2X200000 IE	DE	6274N01
2042053	HEPARIN NATRIUM "MULTI" SET 2X200000 IE	DE	7411N02
2042053	HEPARIN NATRIUM "MULTI" SET 2X200000 IE	DE	8045N01

350592	HEPARIN NATRIUM 5000 IU/ML V 5ML ENG	AE	6375N01
350592	HEPARIN NATRIUM 5000 IU/ML V 5ML ENG	AE	6483N01
3640700	HEPARIN NATRIUM 25.000 IU V 5ML ST.RUS	AZ	6272N01
3640700	HEPARIN NATRIUM 25.000 IU V 5ML ST.RUS	AZ	7055N01
391722	HEPARIN NATRIUM 25.000 IU V 5ML BG	BG	5093N01
391722	HEPARIN NATRIUM 25.000 IU V 5ML BG	BG	6272N01
391722	HEPARIN NATRIUM 25.000 IU V 5ML BG	BG	6481N01
391722	HEPARIN NATRIUM 25.000 IU V 5ML BG	BG	7055N01
391722	HEPARIN NATRIUM 25.000 IU V 5ML BG	BG	7441N01
350592	HEPARIN NATRIUM 5000 IU/ML V 5ML ENG	BH	6375N01
350592	HEPARIN NATRIUM 5000 IU/ML V 5ML ENG	BH	6483N01
350592	HEPARIN NATRIUM 5000 IU/ML V 5ML ENG	BH	7055N01
346643	HEPARIN NATRIUM 25.000 I.E. V 5ML CO	CO	6191N01
346643	HEPARIN NATRIUM 25.000 I.E. V 5ML CO	CO	6272N01
346643	HEPARIN NATRIUM 25.000 I.E. V 5ML CO	CO	6483N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	DE	5093N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	DE	5261N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	DE	6143N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	DE	6191N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	DE	6193N02
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	DE	6382N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	DE	7055N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	DE	7061N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	DE	7063N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	DE	7381N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	DE	7382N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	DE	7384N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	DE	7441N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	DE	8033N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	DE	8035N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	DE	8061N01
350592	HEPARIN NATRIUM 5000 IU/ML V 5ML ENG	FJ	7055N01
350592	HEPARIN NATRIUM 5000 IU/ML V 5ML ENG	GE	6272N01
350592	HEPARIN NATRIUM 5000 IU/ML V 5ML ENG	GE	6375N01
3640700	HEPARIN NATRIUM 25.000 IU V 5ML ST.RUS	GE	6483N01
3640700	HEPARIN NATRIUM 25.000 IU V 5ML ST.RUS	GE	7055N01
350592	HEPARIN NATRIUM 5000 IU/ML V 5ML ENG	JO	7055N01

3640700	HEPARIN NATRIUM 25.000 IU V 5ML ST.RUS	KZ	6272N01
3640700	HEPARIN NATRIUM 25.000 IU V 5ML ST.RUS	KZ	6382N01
3640700	HEPARIN NATRIUM 25.000 IU V 5ML ST.RUS	KZ	6483N01
3640700	HEPARIN NATRIUM 25.000 IU V 5ML ST.RUS	KZ	7055N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	LU	5093N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	LU	5261N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	LU	6143N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	LU	6193N02
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	LU	6382N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	LU	7061N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	LU	7063N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	LU	7382N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	LU	7441N01
350592	HEPARIN NATRIUM 5000 IU/ML V 5ML ENG	LY	6272N01
350592	HEPARIN NATRIUM 5000 IU/ML V 5ML ENG	QA	6375N01
350592	HEPARIN NATRIUM 5000 IU/ML V 5ML ENG	QA	6483N01
333518	HEPARIN SODIUM 25000 IU V 5ML RU	RU	6143N01
333518	HEPARIN SODIUM 25000 IU V 5ML RU	RU	6191N01
333518	HEPARIN SODIUM 25000 IU V 5ML RU	RU	6381N01
333518	HEPARIN SODIUM 25000 IU V 5ML RU	RU	6391N01
333518	HEPARIN SODIUM 25000 IU V 5ML RU	RU	7384N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	SI	5093N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	SI	5093N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	SI	5093N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	SI	5261N01
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	SI	6193N02
2047217	HEPARIN NATRIUM 25000 IE V 5ML DE	SI	7381N01
350592	HEPARIN NATRIUM 5000 IU/ML V 5ML ENG	SR	7055N01
350592	HEPARIN NATRIUM 5000 IU/ML V 5ML ENG	SV	6272N01
350592	HEPARIN NATRIUM 5000 IU/ML V 5ML ENG	SV	6483N01

Rapid Alert Notification of a Quality Defect / Recall	
Regierungspräsidium Darmstadt, 64278 Darmstadt	
1. To / Empfänger:	FAX
<input checked="" type="checkbox"/> Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)	0228-2073515
<input type="checkbox"/> Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL)	01888-4122303
<input type="checkbox"/> Paul-Ehrlich-Institut / Bundesamt für Sera und Impfstoffe (PEI)	06103-771234
<input checked="" type="checkbox"/> Hessisches Sozialministerium (HSM), Referat V 7A Pharmazie	0611-8173850
2. Product Recall Class of Defect: I	3. Counterfeit / Fraud (specify)*
4. Product: please see annex	5. Marketing Authorisation Number: * please see annex For use in humans
6. Brand/Trade Name: please see annex	7. INN or Generic Name: Heparin Sodium
8. Dosage Form: solution for injection	9. Strength: please see annex
10. Batch/Lot Number: please see annex	11. Expiry Date:
12. Pack size and Presentation: please see annex	13. Date Manufactured: *
14. Marketing Authorisation Holder: * please see annex	
15. Manufacturer: B. Braun Medical S.A. Carretera de Terrasa 121 Rubi, Barcelona Spain <i>Place of manufacture:</i> B. Braun Medical S.A. Ronda de los Olivares 5 Poligone Industrial Los Olivares 23009 Jaén Spain Contact Person: Dr. Karin A. Urban Telephone: 05661-71-3965	16. Recalling Firm (if different): Contact Person: Dr. Karin A. Urban Telephone: 05661-71-3965
17. Recall Number Assigned (if available)	

* Information not required, when notified from outside EU.

† The holder of an authorisation referred to under Article 40 of Directive 2001/83/EC or Article 44 of Directive 2001/82/EC and the holder of the authorisation on behalf of whom the Qualified Person has released the batch in accordance with Article 51 of Directive 2001/83/EC or Article 55 of Directive 2001/82/EC if different.

This is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential, and protected from disclosure under applicable law. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify us by telephone immediately and return it to us at the above address by mail. Thank you.

DRINGEND - BITTE SOFORT AUSLIEFERN! IMPORTANT - DELIVER IMMEDIATELY

<p>18. Details of Defect/Reason for Recall: The analysis of the API Heparin used in the recalled batches shows the presence of a contaminant which has now been identified as a glycosamineglycan, oversulfated chondroitin sulfat with a high degree of possibility. Until now no serious adverse events related to the recalled batches have been occurred. The relationship of the serious adverse events reported in the USA and in some cases in europe to the heparin or the contaminant remains unclear.</p>		
<p>19. Information on distribution including exports (type of customer, e.g. hospitals):* Please see annex</p>		
<p>20. Action taken by Issuing Authority: Initiation of recall</p>		
<p>21. Proposed Action: -----</p>		
<p>22. From (Issuing Authority): Regierungspräsidium Darmstadt mail to: pharmazie@rpda.hessen.de</p>	<p>23. Contact Person: Norbert Müller Telephone: 06151-12 – 5277 06408-500539</p>	
<p>24. Signed: Norbert Müller</p>	<p>25. Date: 28.03.2008</p>	<p>26. Time: *</p>

* Information not required, when notified from outside EU.

† The holder of an authorisation referred to under Article 40 of Directive 2001/83/EC or Article 44 of Directive 2001/82/EC and the holder of the authorisation on behalf of whom the Qualified Person has released the batch in accordance with Article 51 of Directive 2001/83/EC or Article 55 of Directive 2001/82/EC if different.

This is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential, and protected from disclosure under applicable law. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify us by telephone immediately and return it to us at the above address by mail. Thank you.

Hessisches Sozialministerium · Postfach 31 40 · D-65021 Wiesbaden

Per Telefax

Bundesinstitut für Arzneimittel und Medizinprodukte

Oberste Landesgesundheitsbehörden

Arzneimittelkommissionen der Apotheker und Ärzte

nachrichtlich:

Landesärztekammer Hessen

Landesapothekerkammer Hessen

Zentralstelle der Länder für Gesundheitsschutz bei
Arzneimitteln und Medizinprodukten

Abwehr von Arzneimittelrisiken

**Rückruf zweier weiterer Chargen der Fertigarzneimittel Heparin Natrium 25 000 I.E. / 5ml
der Firma B. Braun Melsungen AG, Carl-Braun-Str. 1, 34212 Melsungen**

Anlage

RAS-Formular des Regierungspräsidiums Darmstadt mit Annex

Aufgrund analytischer Auffälligkeiten ruft die Fa. B. Braun Melsungen zwei weitere Chargen des
o.g. Arzneimittels zurück, die nach Deutschland, Luxemburg und Slowenien geliefert wurden.

Beiliegend wird das RAS-Formular mit Annex zu den betroffenen Chargen übersandt.

Das Regierungspräsidium Darmstadt überwacht weiterhin den Rückruf.

Im Auftrag

Dr. Michael Binger

Geschäftszeichen (im Antwortschreiben bitte angeben)
VIII 7A 18I 6420

Bearbeiter/in: Herr Dr. Michael Binger

Direkte Kommunikation (Durchwahl):

Telefon: (0611) 8 17 - 3851

Telefax: (0611) 8 17 - 3850

E-Mail: michael.binger@hsm.hessen.de

Wiesbaden,

April 2008

Annex to section 4: Product

Heparin Sodium 25 000 I.U./5 ml
in Germany, Luxembourg, Slovenia

Annex to section 5: Marketing Authorisation Number

DE: 1708.00.00
LU: 667/83/06/0203

Annex to section 6: Brand/Trade Name

DE: Heparin Natrium Braun 25000 I.E./5 ml
LU: Heparin Natrium Braun 25000 I.E./5 ml

Annex to section 9: Strength

all concerned countries
25000 I.U./5 ml

Annex to section 12: Pack size and presentation

all concerned countries
10 x 5 ml glass vials

Annex to section 14: Marketing Authorisation Holder

Germany, Luxembourg, Slovenia

B. Braun Melsungen AG
Carl-Braun-Str. 1
34212 Melsungen, Germany

Annex to section 19: Information on distribution

Germany, Luxembourg, Slovenia

Annex to section 10: batches

Artikelnr.	Bezeichnung		Land	Charge
2047217	HEPARIN NATRIUM 25000 IE	V 5ML DE	DE	7274N01
2047217	HEPARIN NATRIUM 25000 IE	V 5ML DE	DE	7281N01
2047217	HEPARIN NATRIUM 25000 IE	V 5ML DE	LU	7274N01
2047217	HEPARIN NATRIUM 25000 IE	V 5ML DE	LU	7281N01
2047217	HEPARIN NATRIUM 25000 IE	V 5ML DE	SI	7274N01
2047217	HEPARIN NATRIUM 25000 IE	V 5ML DE	SI	7281N01

DRINGEND - BITTE SOFORT AUSLIEFERN! IMPORTANT - DELIVER IMMEDIATELY

Rapid Alert Notification of a Quality Defect / Recall	
Regierungspräsidium Darmstadt, 64278 Darmstadt	
1. To / Empfänger:	FAX
<input checked="" type="checkbox"/> Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)	0228-2073515
<input type="checkbox"/> Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL)	01888-4122303
<input type="checkbox"/> Paul-Ehrlich-Institut / Bundesamt für Sera und Impfstoffe (PEI)	06103-771234
<input checked="" type="checkbox"/> Hessisches Sozialministerium (HSM), Referat V 7A Pharmazie	0611-8173850
2. Product Recall Class of Defect: I	3. Counterfeit / Fraud (specify)*
4. Product: Heparin Sodium 25 000 I.U./5 ml	5. Marketing Authorisation Number: * DE: 1708.00.00, LU: 667/83/06/0203 For use in humans
6. Brand/Trade Name: Heparin Natrium Braun 25000 I.E./5 ml	7. INN or Generic Name: Heparin Sodium
8. Dosage Form: solution for injection	9. Strength: 25000 I.U./5 ml
10. Batch/Lot Number: 7274N01, 7281N01	11. Expiry Date:
12. Pack size and Presentation: 10 x 5 ml glass vials	13. Date Manufactured: *
14. Marketing Authorisation Holder: * B. Braun Melsungen AG Carl-Braun-Str. 1 34212 Melsungen, Germany	
15. Manufacturer: B. Braun Medical S.A. Carretera de Terrasa 121 Rubi, Barcelona Spain <i>Place of manufacture:</i> B. Braun Medical S.A. Ronda de los Olivares 5 Poligono Industrial Los Olivares 23009 Jaén Spain Contact Person: Dr. Karin A. Urban Telephone: 05661-71-3965	16. Recalling Firm (if different): Contact Person: Dr. Karin A. Urban Telephone: 05661-71-3965
17. Recall Number Assigned (if available)	

* Information not required, when notified from outside EU.

† The holder of an authorisation referred to under Article 40 of Directive 2001/83/EC or Article 44 of Directive 2001/82/EC and the holder of the authorisation on behalf of whom the Qualified Person has released the batch in accordance with Article 51 of Directive 2001/83/EC or Article 55 of Directive 2001/82/EC if different.

This is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential, and protected from disclosure under applicable law. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify us by telephone immediately and return it to us at the above address by mail. Thank you.

DRINGEND - BITTE SOFORT AUSLIEFERN! IMPORTANT - DELIVER IMMEDIATELY

18. Details of Defect/Reason for Recall: The analysis of the API Heparin used in the recalled batches shows the presence of a contaminant which has now been identified as a glycosamineglycan, oversulfated chondroitin sulfat with a high degree of possibility. Until now no serious adverse events related to the recalled batches have been occurred. The relationship of the serious adverse events reported in the USA and in some cases in europe to the heparin or the contaminant remains unclear.		
19. Information on distribution including exports (type of customer, e.g. hospitals):* Germany, Luxembourg, Slovenia		
20. Action taken by Issuing Authority: Initiation of recall		
21. Proposed Action: -----		
22. From (Issuing Authority): Regierungspräsidium Darmstadt mail to: pharmazie@rpda.hessen.de	23. Contact Person: Norbert Müller Telephone: 06151-12 – 5277 06408-500539	
24. Signed: Norbert Müller	25. Date: 01.04.2008	26. Time: *

* Information not required, when notified from outside EU.

† The holder of an authorisation referred to under Article 40 of Directive 2001/83/EC or Article 44 of Directive 2001/82/EC and the holder of the authorisation on behalf of whom the Qualified Person has released the batch in accordance with Article 51 of Directive 2001/83/EC or Article 55 of Directive 2001/82/EC if different.

This is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential, and protected from disclosure under applicable law. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify us by telephone immediately and return it to us at the above address by mail. Thank you.